Literature DB >> 30972803

Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives.

Xin Sun1, Peiyi Yan2, Chang Zou3, Yin-Kwan Wong4, Yuhan Shu5, Yew Mun Lee4, Chongjing Zhang6, Nai-Di Yang4, Jigang Wang3,4,7,8, Jianbin Zhang1.   

Abstract

Artemisinin and its derivatives, with their outstanding clinical efficacy and safety, represent the most effective and impactful antimalarial drugs. Apart from its antimalarial effect, artemisinin has also been shown to exhibit selective anticancer properties against multiple cancer types both in vitro and in vivo. Specifically, our previous studies highlighted the therapeutic effects of artemisinin on autophagy regulation. Autophagy is a well-conserved degradative process that recycles cytoplasmic contents and organelles in lysosomes to maintain cellular homeostasis. The deregulation of autophagy is often observed in cancer cells, where it contributes to tumor adaptation to nutrient-deficient tumor microenvironments. This review discusses recent advances in the anticancer properties of artemisinin and its derivatives via their regulation of autophagy, mitophagy, and ferritinophagy. In particular, we will discuss the mechanisms of artemisinin activation in cancer and novel findings regarding the role of artemisinin in regulating autophagy, which involves changes in multiple signaling pathways. More importantly, with increasing failure rates and the high cost of the development of novel anticancer drugs, the strategy of repurposing traditional therapeutic Chinese medicinal agents such as artemisinin to treat cancer provides a more attractive alternative. We believe that the topics covered here will be important in demonstrating the potential of artemisinin and its derivatives as safe and potent anticancer agents.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  artemisinin; artesunate; autophagy; cancer; ferritinophagy; heme; lysosome; mammalian target of rapamycin; mitophagy

Mesh:

Substances:

Year:  2019        PMID: 30972803     DOI: 10.1002/med.21580

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  20 in total

1.  [Isobavachalcone induces cell death through multiple pathways in human breast cancer MCF-7 cells].

Authors:  Y Zhang; M Gao; M Zhu; H Li; T Ma; C Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-06-20

2.  Therapeutic efficacy of antimalarial drugs targeting DosRS signaling in Mycobacterium abscessus.

Authors:  Juan Manuel Belardinelli; Deepshikha Verma; Wei Li; Charlotte Avanzi; Crystal J Wiersma; John T Williams; Benjamin K Johnson; Matthew Zimmerman; Nicholas Whittel; Bhanupriya Angala; Han Wang; Victoria Jones; Véronique Dartois; Vinicius C N de Moura; Mercedes Gonzalez-Juarrero; Camron Pearce; Alan R Schenkel; Kenneth C Malcolm; Jerry A Nick; Susan A Charman; Timothy N C Wells; Brendan K Podell; Jonathan L Vennerstrom; Diane J Ordway; Robert B Abramovitch; Mary Jackson
Journal:  Sci Transl Med       Date:  2022-02-23       Impact factor: 19.319

Review 3.  Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting.

Authors:  Xianglei Fu; Yanbin Shi; Tongtong Qi; Shengnan Qiu; Yi Huang; Xiaogang Zhao; Qifeng Sun; Guimei Lin
Journal:  Signal Transduct Target Ther       Date:  2020-11-06

Review 4.  Artemisinin-type drugs for the treatment of hematological malignancies.

Authors:  R I Mancuso; M A Foglio; S T Olalla Saad
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-03       Impact factor: 3.333

Review 5.  Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing.

Authors:  Yolanda Augustin; Henry M Staines; Sanjeev Krishna
Journal:  Pharmacol Ther       Date:  2020-10-16       Impact factor: 12.310

6.  A novel Diels-Alder adduct of mulberry leaves exerts anticancer effect through autophagy-mediated cell death.

Authors:  Yu-Han Shu; Hua-Hua Yuan; Meng-Ting Xu; Ye-Ting Hong; Cheng-Cheng Gao; Zhi-Pan Wu; Hao-Te Han; Xin Sun; Rui-Lan Gao; Si-Fu Yang; Shou-Xin Li; Jing-Kui Tian; Jian-Bin Zhang
Journal:  Acta Pharmacol Sin       Date:  2020-08-19       Impact factor: 6.150

7.  Nujiangexanthone A Inhibits Cervical Cancer Cell Proliferation by Promoting Mitophagy.

Authors:  Jiling Feng; Anahitasadat Mansouripour; Zhichao Xi; Li Zhang; Gang Xu; Hua Zhou; Hongxi Xu
Journal:  Molecules       Date:  2021-05-12       Impact factor: 4.411

Review 8.  Progress in Redirecting Antiparasitic Drugs for Cancer Treatment.

Authors:  Haoyang Huang; Qing He; Binghua Guo; Xudong Xu; Yinjuan Wu; Xuerong Li
Journal:  Drug Des Devel Ther       Date:  2021-06-22       Impact factor: 4.162

9.  Artesunate inhibits epithelial-mesenchymal transition in non-small-cell lung cancer (NSCLC) cells by down-regulating the expression of BTBD7.

Authors:  Jing-Si Wang; Ming-Juan Wang; Xiao Lu; Jiao Zhang; Quan-Xing Liu; Dong Zhou; Ji-Gang Dai; Hong Zheng
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

10.  Dihydroartemisinin-Loaded Magnetic Nanoparticles for Enhanced Chemodynamic Therapy.

Authors:  Shengdi Guo; Xianxian Yao; Qin Jiang; Kuang Wang; Yuanying Zhang; Haibao Peng; Jing Tang; Wuli Yang
Journal:  Front Pharmacol       Date:  2020-03-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.